Ad hoc announcement pursuant to Art. 53 LR
Treatment with evenamide demonstrated significant, clinically important, progressive, sustained and long-lasting improvement on PANSS
Ad hoc announcement pursuant to Art. 53 LR
290 patients participate at study centers in Europe, Asia and Latin America
Results from the study are expected in March 2024
Ad hoc announcement pursuant to Art. 53 LR
40% of patients no longer met TRS severity criteria
Company presented data from study in treatment resistant schizophrenia (TRS)
Poster presentations will include the full results from all 161 patients randomized in study 014 at the six-month time point from extension study 015, a Phase II trial evaluating
Margarita Chavez, former Managing Director at AbbVie Ventures, to be nominated for election to the Board of Directors at the Ordinary AGM 2024
Milan, Italy, October 2, 2023 –
Ad hoc announcement pursuant to Art. 53 LR
Milan, Italy, August 4, 2023, 7 am CET – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical
Study 014/015 is a Phase II trial evaluating evenamide as add-on therapy for patients with treatment-resistant schizophrenia (TRS)
Full data from first 100 patients at the one-
Further data from study 014/015 of evenamide in treatment-resistant schizophrenia (TRS) confirms potentially relevant role of glutamatergic release modification when added to TRS
Ad hoc announcement pursuant to Art. 53 LR
Milan, Italy, May 2, 2023, 7 am CET – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company
Milan, Italy, April 18, 2023 – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for
The information on the following pages may be made available in the United States. By clicking on the link below, you agree that you are in the United States.
